Source:http://linkedlifedata.com/resource/pubmed/id/20674757
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2011-2-14
|
| pubmed:abstractText |
We investigated the administration of intravenous (i.v.) busulfan (Bu) combined with melphalan (Mel) in patients with advanced lymphoid malignancies undergoing autologous stem cell transplantation. Bu 130 mg/m(2) was infused daily for 4 days, either as a fixed dose per body surface area (BSA), or to target an average daily area under the curve of 5000 ?mol-min, determined by a test dose of i.v. Bu at 32 mg/m(2) given 48 hours prior to the high-dose regimen, followed by a rest day, followed by 2 daily doses of Mel at 70 mg/m(2). Stem cells were infused the following day. Eighty patients had i.v. Bu delivered per test dose guidance. The median daily systemic Bu exposure was 4867 ?mol-min. One hundred two patients (Hodgkin lymphoma n = 49, non-Hodgkin lymphoma n = 12, multiple myeloma = 41) with a median age of 44 years (range: 19-65 years) were treated. The 2-year overall survival and progression-free survival rates were 85% and 57%, respectively, for patients with Hodgkin lymphoma, 67% and 64%, respectively, for patients with non-Hodgkin lymphoma, and 82% and 42%, respectively, for patients with multiple myeloma. The regimen was very well tolerated with treatment-related mortality at 100 days, 1 year, and 2 years of 1%, 3%, and 3%, respectively. Intravenous Bu-Mel was well tolerated. Disease control wa encouraging, and should be explored in larger phase II studies.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1523-6536
|
| pubmed:author |
pubmed-author:AnderssonBorje SBS,
pubmed-author:ChamplinRichard ERE,
pubmed-author:HosingChitraC,
pubmed-author:JonesRoy BRB,
pubmed-author:KazerooniRezaR,
pubmed-author:KebriaeiPartowP,
pubmed-author:KhouriIssaI,
pubmed-author:LedesmaCelinaC,
pubmed-author:MaddenTimothyT,
pubmed-author:NietoYagoY,
pubmed-author:PopatUdayU,
pubmed-author:QazilbashMuzaffarM,
pubmed-author:ShpallElizabeth JEJ,
pubmed-author:ThallPeter FPF,
pubmed-author:WangXuemeiX
|
| pubmed:copyrightInfo |
Copyright © 2011. Published by Elsevier Inc.
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
17
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
412-20
|
| pubmed:meshHeading |
pubmed-meshheading:20674757-Adult,
pubmed-meshheading:20674757-Aged,
pubmed-meshheading:20674757-Antineoplastic Agents, Alkylating,
pubmed-meshheading:20674757-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20674757-Busulfan,
pubmed-meshheading:20674757-Female,
pubmed-meshheading:20674757-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:20674757-Hodgkin Disease,
pubmed-meshheading:20674757-Humans,
pubmed-meshheading:20674757-Infusions, Intravenous,
pubmed-meshheading:20674757-Lymphoma, Non-Hodgkin,
pubmed-meshheading:20674757-Lymphoproliferative Disorders,
pubmed-meshheading:20674757-Male,
pubmed-meshheading:20674757-Melphalan,
pubmed-meshheading:20674757-Middle Aged,
pubmed-meshheading:20674757-Multiple Myeloma,
pubmed-meshheading:20674757-Severity of Illness Index,
pubmed-meshheading:20674757-Survival Analysis,
pubmed-meshheading:20674757-Transplantation, Autologous,
pubmed-meshheading:20674757-Transplantation Conditioning,
pubmed-meshheading:20674757-Young Adult
|
| pubmed:year |
2011
|
| pubmed:articleTitle |
Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.
|
| pubmed:affiliation |
Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA. pkebriae@mdanderson.org
|
| pubmed:publicationType |
Journal Article,
Clinical Trial
|